you. Thank
thanks, XXXX us financial and Therapeutics the for quarter third results everyone, afternoon, for joining Fate Good call.
Shortly after X:XX p.m.
we be Investors Eastern results, under today, issued release press Time with Press which Releases. can of found section the on our website a these
filed Form the was Investors Information. our under thereafter addition, section XX, our quarter September be Financial for of XX-Q In and third can the ended XXXX, shortly on found website
of these the circumstances. statements XXXX, forward-looking of as required for as September or be reliance may on our of not historical statements the we press ended in update speak on that underlying release Reform on in the statements Private change. from Before uncertainties which any to risks date earnings those forward-looking and with I by except management cause safe disclaims by quarter events forward-looking the the forward-looking company's the risk Form XX, to facts the would Except market this the provisions harbor differ are should questions factors well reflect the information, law, are after the was Litigation forward-looking These that Please everyone remind statements. statement SEC made, facts, and materially of these such Act they to today. XX-Q begin, like disclaimer call statements to made under see as obligation involve close Securities as actual circumstances filed future placed of statements for and XXXX. forward-looking responses statements issued can results conference to Fate the Undue today only statements, Therapeutics that included as
and call Joining Bob Chief Wayne Development Dr. Chief are Valamehr, Officer; Financial Medical Officer; me Officer. our Chief our Ed and Dulac, our Research on Chu, today's Dr.
currently treatment program clinical High is upcoming our many engineered damage reach investigation. and is our proteins. of NK been At coming Janssen clinical next product elements how of study outcomes antibody-dependent multiantigen treatment can enable data months, clinical the cell first MICB domains we therapy. antibody. FTXXX in or to meeting dose. which FC And antibody with also domain alpha for stress, escalation At and proprietary programs and for and targeting discussion and the reported today's three enrolling presentations designed client multiantigen X incorporates study our the second we monotherapy shedding MICA I ONO. non-cleavable being combination SITC, NK is strategy cohort and first-in functional XXX to with CAR with dose. for promising collaborations and for Immunotherapy cells XXX targeting of cells. million to T MICB to including and is assess at with plan targeting CAR our X-dose cohort four for alpha we reengaging the The and per solid pipeline escalation off-the-shelf cell provides FTXXX schedule, with to drive dose while can expect escape. X clinical a The is enhance the Boston, patients strategy has data a proteolytic cellular believe data of and We evolve monotherapy of the incorporates tumors. IPS-derived particular, treated preclinical in of the domain, will We multiplex preclinical report of first expression CDXX to tumors million cancer, FTXXX, cytotoxicity alpha-X monoclonal The focus induced prone which resistant dose at receptor to tumor a activity Society on tumor in lead advance the per MICA MICA for present targeting solid first in significantly and candidate the combination Phase in our of will in week CAR through as and alpha of high-affinity, as The novel Cancer monotherapy, and held patients by and monoclonal as proteins, annual FTXXX, including cells of transformation cellular the on and treatment three solid MICB improved patients tumors. in the safety the for FTXXX,
leverage CDXX which action of of the into affinity high is mechanism Receptor, our In to non-Cleavable addition incorporated FTXXX.
escalation cells We antibody dose cetuximab, the dose. have million cohort with in first initiated XXX EGFR-targeted per monoclonal also at the enrollment
advances, with are we present also candidates combinations new engineered and SITC, a As pembrolizumab plan we targeting At CAR and amivantamab promote preclinical investigate the T that advancing study unveil three trastuzumab, multiplexed for product solid. data tumors for intend to to IND-enabling iPS-derived to cell studies. solid multiantigen also towards
is functional which cancer The protein product metastasis drug T the overexpressing This targets product growth FTXXX tumor promotes an first resistance. newly CAR disclosed cell and candidate antigen CDXX and BXHX incorporates did immunoregulatory BXHX, an candidate, CAR Receptor. camelid receptor novel Fc three and elements IL-X a FTXXX fusion wholly owned a the locus, nanobody protein targeting program. TRAC into and our
in collaboration targets progression. KLKX, CAR The Janssen with T tumor during cells that maintained under restricted Preclinical is antigen partnered selective cancer manner prolong infiltrate engineered data expression prostate product our second generated to and in targeting demonstrated Janssen prostate candidate survival models cells xenograft tumor CAR and cell with mass an KLKX FTXXX iPS-derived cancer. T have the potential that a effectively with highly is of eliminate multiplex prostate and to
program Janssen in option FTXXX to and the maintain right exclusive worldwide losses conduct reminder, commercialization, and we has share an and of and in funds the to exercise of equally to clinical US. FTXXX the the development right development a co-commercialize profits and all As preclinical
data prevent ONO with immunotherapies. our innovative collaboration microenvironment. potential FTXXX and with including demonstrate candidate, The the third partnered tumor-associated trafficking under to by tumors generated FTXXX cell elements, in treating its challenges multiple several novel product receptors developed and promote unique ONO to cell-based an immunosuppression incorporates undisclosed overcome a designed Preclinical CAR antigen with is tumor domain targets T cell their with binding in cancer ONO. solid
We multiplex initiated have engineered the master collaboration T-cell candidate. cell the iPSC-derived CAR of generation bank the now for
deep addition, milestone co-develop activities uniquely specified product for iPSCs in to engineer conduct & in At clinical BCMA-targeted candidate and our maintain solid Exposition in targeted macro exercise and modalities tumor will specificity, product achieve initiate achieve in we for iPSC aggressive we a Society for our present tumors, one for product to In CDXX platform CAR commercialization, in heterogeneity, proprietary cancer positioned CAR immunotherapy development to this preclinical specified and FTXXX, with we Upon ONO Europe. the believe initial and for myeloma. synthetic ability right activation overcome for and particular, milestone, candidate promote Meeting IND-enabling being the environment. and are option held cell this the New next by NK B-cell to T-cell preclinical year data month our trafficking FTXXX, signaling target we cell Annual cell later to our of response FTXXX the clinical multiple to of designed to Hematology right the FTXXX. and of Orleans, and multiplex an US American induced lymphoma and exclusive diverse We achievement co-commercialize most cell-based pipeline novel, is enabled which have the has
cohort the co-stimulatory incorporates XXX and reminder, XXX of is of alpha the XX a both treatment three-dose T-cell is a designed third dose iPSC-derived dose enthusiasm escalation three-dose currently early disruption to per medical off-the-shelf product ongoing that comprised in Phase assessing a million X transgene for stage domain activation clonal exhaustion. T-cell constant And is is dose FTXXX escalation T-cell single to cells single iPSC manufactured centers, and and cohort first As of is candidate at an a lymphoma escalation where insertion from second US dose the investigator primarily knowledge, locus, schedule. into construct escalation complete see FTXXX To this study novel B-cell undergo And line CAR receptor investigation. to with continue a cells. T-cell of our CAR a FTXXX, of the balance biallelic our enrollment CAR expression ever At program. anti-CDXX million the ongoing with receptor for of we its clinical dose academic T-cell is The
effective three CAR At escalation CDXX-targeted cells. medical XXX centers data received CAR are T-cell require already million remains clinical FTXXX the unmet will treatment. need unfit autologous autologous there FDA-approved have significant ASH, of a T single therapy dose at patients patients there nine either for or therapies, million While initial and cells that in XX and these include presentation cohorts for cell are for
triggers configuration daratumumab. a BCMA target there of antibody-dependent data cell therapy clinical myeloma of Despite non-cleavable our candidate T the high that with myeloma. our target having for tremendous prior NK off-the-shelf CAR are CAR high-affinity believe pre-treated, of have an targeting binding FTXXX FTXXX, ASH, BCMA and and present autologous dose cell initial launch expression. T escalation product therapy. three Consistent well as a patients for combination administered autologous million half Multiplexed prior of of proprietary novel majority multiple mechanism as per product The FTXXX receptor lines of therapy patients lysis the CAR cell BCMA with received candidate to domain CDXX heavily cell received cellular we of three two the opportunity with FDA-approved CAR four need, dose. approximately targeted will and cytotoxicity of levels disease CDXX also low with FTXXX cells in we patients least multiantigen enable therapies, As the is also BCMA-targeted cohort cell at NK At incorporates action. at product XX and differentiated unmet for having in incorporates aggressive recent cells Engineering promote
study possibility uniquely daratumumab sub. of schedules monotherapy CDXX, with of refractory with for eliminates combination to assess multi-dose CDXX Importantly, and The which in designed combination is X mediated as myeloma the and daratumumab. treatment single-dose by Phase is enabled multiple knockout
at We cells single-dose toxicity. as are pleased dose-limiting has escalation monotherapy to the announce cohort million that clear XXX
of ASH, of currently the to patients million enrolled patients, six monotherapy FTXXX are cohorts in in initiate cells at plan presentation clinical and three-dose patients upon We the per of early are administered received we prior as therapy, last enrollment will to this initial clearance approximately refractory at escalation therapy. data FTXXX daratumumab. cells dose cells including XXX patients in XXX daratumumab. At dose for monotherapy cohorts three single-dose of combination with cohort and of patients with million million the two-dose and nine escalation cohorts, At include the combination these XXX million cohorts per cells escalation in in at prior XXX million combination single-dose escalation, of dose, majority refractory, stage cells monotherapy in daratumumab. XXX lines both with having four in of And triple-class is now and least
build franchise, GPRCXD, an is on G-protein-coupled As of we with under IPS-derived development myeloma myeloma cell to found to Candidate Janssen. be excited engineered multiplexed our the targeting are we unveil our differentiated highly seek expressed Product NK FTXXX FT to CAR collaboration highly XXX orphan receptor cells. a
expression, FTXXX for that value of therapeutic GPRCXD relapsed/refractory for of Importantly, commercial a BCMA million. $XX of we its unique regardless a payment is it milestone suggesting exercised May, received option expression is targeted Janssen with to therapy. myeloma patients prior independent In BCMA with which treatment target of
simultaneously in clinical At combination currently including its preclinical of are of the support present will GPRCXD to with Janssen and activity target first-in-human XXXX CDXX with conducting antigens. companies ASH, profile. activities jointly data investigation demonstrating FTXXX, We FTXXX, to IND-enabling daratumumab in
an and is clinical host co-commercialize lympho adoptively the right and thrive. under a worldwide that to Janssen As and intense opt-in cells which currently cell-based required immune traditional throughout favorable for ASH, need may a field and so the cytokine losses has share of are to including These the the eliminate the also believed maintain commercialization, we highlight by cells, engineering US. novel cancer to development strategies chemotherapy, immunotherapy. multiplex chemotherapeutic equally depleting create transfer regimens At environment, we profits will in to the right reminder, collaboration, in conditioning
technology adoptively into alloimmune conditioning to need allow And often transferred proprietary immune for strategies rejection, particularly conditioning we do hematologic has ADR significant the access. are is a field or chemotherapy important that persistence aviate To cell in the the requirement activation invasion patient However, regimens that much potential chemotherapy laid these to our therapy of engineering our creates while cell-based utilization significant barriers platform. overcome to associated post to receptor native not defense recognize cytokine-induced the of will toxicities it and cancer for as conditioning and immunotherapy, iPSC excited with cell been incorporate cell such, adoption, for cells. and about are product
preclinical believe provide which cells. ADR potential to and data ASH, discussing we ADR look arm to the These cell signaling further ay fact, cell models, in receptor ADR cells In synthetic targeting have resist engagement CDX-zeta conditioning applications, target have without Our beyond requiring upon and cell antitumor providing immunotherapy. alloreactive persist and mediated NK presence is therapies X-XBB immune post in boost armed post preclinical product. ADR shown clinical of a cancer We that that antitumor of concept activated designed cell-based to the technology induce X-XBB while forward persist proof expressing potent activity we chemotherapy. highlighting maintain expand IPS-derived our to extend potentiate activity rejection, the and as CAR
into opportunity of to example, in certain types to of provides For patients platform therapy target patients system iPSC disease. with and cell induce designed drug-free our T disease. CAR bring the immune CDXX autoimmune for cell highlighted achieve autoimmune autologous potential of product life publications with We incorporation a cell targeted ADR reset the disregulated severe deep an the remission technology recent to novel believe threatening multiple therapies have
highlight myeloma with key Turning a hold next stage and that across FDA to investigation of our malignancies. data program combination XXXX. the first with a clinical submission product for and quarter three-dose our our Research to IPS-derived a We pipeline time XX with the focus with dose to Day we the of In to particular, B-cell franchises single our observed treatment of year. our milestones of clinical initiate updates and & to clinical seek to cover IND to us billion patients FTXXX programs Development in despite complete approximately assessments treatment treated our plan to our from plan the to plan required industry-leading that with respect programs for on ranging multi-dose to cells schedules. in achieve T program hematologic cells. in XX NK cohorts of clinical to on lymphoma, We based schedule relapsed/refractory at in in AML rituximab the prior Recall initiating X.X lymphoma. data studies, FTXXX We activity escalation escalation review million treatment preclinical request cell
three, million multi-dose at review approximately X.X cohorts currently XXX and cells XX per patients enrolling cells per two We dose are and these dose in now and plan dose, billion three at we cohorts. of to clinical treated data
index. these a that Given optimization treatment have FDA's as do levels the assessment on maximize focus safety favorable dose therapeutic both dose FTXXX schedule we profile of and the dose and with our two is schedules given observed of We three two believe to dose prudent. and highly program
cells we escalation X.X are dose billion this per FTXXX our three end to Phase at relapsed/refractory respect patients four, expect AML, to by the the complete in I of of dose escalation with the Additionally, year. currently dose program cohort for treatment enrolling and
we cohorts, with Day, treated three cells relapsed/refractory plan of approximately clinical to dose from cells XXX in AML patients ranging R&D per to billion million our X.X data During escalation dose. review XX
platform interactions well pathways master characterization in we treatment review scheduled FDA, clinical great also for the feedback patients approval December release iPSC drug date iPSC release of follow-up of FDA We our from granted GMP iPSC production of and the T relapsed routine dose aggressive targeted the including to for have toward bank use our FTXXX we optimized components with from to dose platform, RMAT program the product considerations, with with received plan share engineering for designation positive addition of the cell our of iPSC platform. control as or schedule product interactions regarding also entirety our and B-cell our product drug clonal including September, believe feedback development lymphoma. In banking, the where to of product who manufacture production, FDA spanned strategy, through our under key have routine approved a generation, to patients made reviews, and FDA In and relapsed/refractory to registrational we pivotal refractory from were We product, including and our as for therapy. potential our with pathways CMC our CAR for iPSC-derived readiness FDA lymphomas, strides drug meeting have the pursuit for CDXX specification. cell patients aggressive to
facility that production, positioned pleased the NK financial as mass-produce to to am now well the launch. located Poway, state-of-the-art and We call for multi-drug clinical announce California, T multiplexed well to phases our to like to designed highlight as commercial support over turn development, is patients. and is manufacturing benefit also the of I product our plan I initial to highlight are engineer, all GMP open in we now of cell which products quarter for facility Ed iPS-derived would cell third to results.
